LAVAL, Quebec–(BUSINESS WIRE)– Altasciences heeft vandaag de voortdurende uitbreiding aangekondigd van hun faciliteiten voor formulering, productie en analytische diensten in Philadelphia, PA. Altasciences, een geïntegreerd bedrijf voor de ontwikkeling van geneesmiddelen dat farmaceutische en biotechnologische bedrijven over de hele wereld een bewezen, flexibele benadering biedt van preklinische en klinische farmacologie studies, inclusief formulerings-, productie- en analytische diensten, lanceerde een tweede bouwproject om de capaciteit te vergroten en tegemoet te komen aan de steeds groeiende behoeften van haar klanten.

De eerste magazijnuitbreiding van Altasciences begon eerder dit jaar en zal naar verwachting eind 2021 klaar zijn voor gebruik. De 35.000 vierkante meter grote ruimte, die in december 2020 is verworven, grenst direct aan de bestaande faciliteit van Altasciences. De nieuwe ruimte, met zijn plafonds van 24 voet, zal worden geconfigureerd met een magazijn van ~ 8750 vierkante voet, een C/D-productiegebied van ~ 8750 vierkante voet en een klantspecifieke cGMP van 17.500 vierkante voet. productie gebied.

Altasciences Continues Building Expansion with Additional Location in Philadelphia

LAVAL, Quebec–(BUSINESS WIRE)– Altasciences today announced the continued expansion of their formulation, manufacturing, and analytical services facilities in Philadelphia, PA. Altasciences, an integrated drug development solution company offering pharmaceutical and biotechnology companies worldwide a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services, launched a second building project to increase its capacity and meet the ever-growing needs of its clients.

Altasciences’ first warehouse expansion started earlier this year and is expected to be ready for use by the end of 2021. The 35,000-square-foot space, acquired in December 2020, is directly adjacent to Altasciences’ existing facility. The new space, with its 24-foot ceilings, will be configured to include a ~8,750-square-foot warehouse, a ~8,750-square-foot Grade C/D manufacturing area, and a 17,500-square-foot client-dedicated cGMP manufacturing area.

In addition, Altasciences has expanded into a new 53,000-square-foot, client-dedicated facility for formulation development and Phase I through to commercial manufacturing. This new project is expected to be completed in 2023.

“Completing these significant expansions and investment into both capacity and state-of-the-art technology will ensure that Altasciences can provide the drug development solutions that our customers need now and in the future. Altasciences prides itself on listening to what our clients need, and then adapting to their requirements,” explained Ben Reed, Executive Vice President of Operations.

About Altasciences

Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210927005549/en/

Contacts

Julie-Ann Cabana

Altasciences
+1 514 601-9763

jcabana@altasciences.com